Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

Published:2019-08-20 Issue:10 Volume:36 Page:2600-2617
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Incorvaia Lorena,Fanale Daniele,Badalamenti Giuseppe,Barraco Nadia,Bono Marco,Corsini Lidia Rita,Galvano Antonio,Gristina Valerio,Listì Angela,Vieni Salvatore,Gori Stefania,Bazan Viviana,Russo Antonio^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-019-01057-7.pdf

Reference76 articles.

1. Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2015;13(3):143–58. https://doi.org/10.1038/nrclinonc.2015.209 .

2. Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015. https://doi.org/10.18632/oncotarget.3204 .

3. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–72. https://doi.org/10.1038/nrc3973 .

4. Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology. 2015;145(2):182–201. https://doi.org/10.1111/imm.12459 .

5. He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015. https://doi.org/10.1038/srep13110 .

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of the Immune Microenvironment in Endometrial Cancer;Laboratory Investigation;2024-09

2. Rediscovering immunohistochemistry in lung cancer;Critical Reviews in Oncology/Hematology;2024-08

3. Vitreoretinal metastasis from lung adenocarcinoma;Canadian Journal of Ophthalmology;2024-08

4. Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review;Cancers;2024-06-26

5. Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by¹⁸F-BMS-986192 PET: pooled analysis of data from four solid tumor types;Journal for ImmunoTherapy of Cancer;2024-06